Douala General Hospital, P.0. Box 4856, Douala, Cameroon.
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
BMC Infect Dis. 2018 Jul 3;18(1):298. doi: 10.1186/s12879-018-3204-8.
The introduction of anti-retroviral treatment (ART) has significantly reduced mortality and morbidity associated with HIV/AIDS. While treatment at early stages of the disease is related to a better prognosis, late presentation (LP) to care is harmful to the infected person, the society and is more costly. We aimed to describe late presentation to HIV care, its associated factors and consequences in patients followed up in a tertiary hospital in Cameroon.
We retrospectively assessed patients' files between 1996 and 2014 at the Douala general hospital (DGH) HIV treatment centre. Late presentation (LP) to HIV care was defined as a CD4+ T cell count< 350 cells/mm3 or advanced clinical stages of the disease (WHO stages 3/4) at first presentation for care. We used logistic regression to study factors associated with late presentation and assessed occurrence of opportunistic infections and mortality at 3, 6 and 12 months after presentation to care.
Of 1866 files studied, mean age was 40 (SD: 10) years, median CD4+ T cell count was 147 (IQR: 63-270) cells/mm3, 58.2% were at HIV clinical stages 3 and 4. The prevalence of late presentation to HIV care was 89.7% (95% CI: 88.2-91.0%) and remained above 80% from 1996 to 2014. Circumstances of diagnosis: prevention of mother to child transmission program/blood donation (OR = 0.16, 95% CI 0.10-0.29), having a positive partner (OR = 0.16, 95%CI = 0.10-0.26), and routine screening (OR = 0.13, 95%CI = 0.10-0.19) reduced the odds of presenting late compared to clinical suspicion. Students had lower odds of presenting late compared to people who had an employment (OR = 0.50, 95%CI = 0.26-0.98). Calendar time OR = 1.64, 95% CI = 1.08-2.48 for ≥2010 vs. < 2005) increased the odds of late presentation. Mortality and opportunistic infections prevalence remained significantly higher in late presenters at 3, 6 and 12 months than in early presenters.
Late presentation to HIV care is very high at the DGH and is related to poor outcome. More screening and sensitization campaigns should be carried out in the population to diagnose the disease at an earlier stage.
抗逆转录病毒治疗(ART)的引入显著降低了与 HIV/AIDS 相关的死亡率和发病率。虽然在疾病早期进行治疗与更好的预后相关,但晚期就诊(LP)会对感染者、社会造成危害,且治疗费用更高。我们旨在描述喀麦隆一所三级医院接受治疗的患者的晚期就诊情况、相关因素及其后果。
我们对 1996 年至 2014 年期间在杜阿拉综合医院(DGH)艾滋病毒治疗中心的患者病历进行了回顾性评估。晚期就诊被定义为首次就诊时 CD4+ T 细胞计数<350 个细胞/mm3 或出现晚期临床疾病(世卫组织 3/4 期)。我们使用逻辑回归分析研究与晚期就诊相关的因素,并评估就诊后 3、6 和 12 个月时机会性感染和死亡率的发生情况。
在 1866 份研究档案中,平均年龄为 40(标准差:10)岁,中位数 CD4+ T 细胞计数为 147(IQR:63-270)个细胞/mm3,58.2%的患者处于 HIV 临床 3 期和 4 期。晚期就诊的比例为 89.7%(95%CI:88.2-91.0%),且从 1996 年到 2014 年一直保持在 80%以上。诊断情况:母婴传播预防项目/献血(OR=0.16,95%CI:0.10-0.29)、阳性伴侣(OR=0.16,95%CI:0.10-0.26)和常规筛查(OR=0.13,95%CI:0.10-0.19)降低了晚期就诊的可能性。与有工作的人相比,学生(OR=0.50,95%CI:0.26-0.98)晚期就诊的可能性较低。与 2005 年之前相比,2010 年及以后(OR=1.64,95%CI:1.08-2.48)的日历时间增加了晚期就诊的可能性。与早期就诊者相比,晚期就诊者在就诊后 3、6 和 12 个月时的死亡率和机会性感染发生率仍然显著较高。
DGH 的晚期就诊率非常高,且与不良预后相关。应在人群中开展更多的筛查和宣传活动,以便在疾病早期进行诊断。